Cargando…

Targeting of the alpha(v) beta(3) integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma

BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) and glioblastoma (GBM) are two highly aggressive and generally incurable gliomas with little therapeutic advancements made in the past several decades. Despite immense initial success of chimeric antigen receptor (CAR) T cells for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cobb, Dustin A, de Rossi, Jacopo, Liu, Lixia, An, Erin, Lee, Daniel W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883284/ https://www.ncbi.nlm.nih.gov/pubmed/35210306 http://dx.doi.org/10.1136/jitc-2021-003816

Ejemplares similares

Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression
por: Mueller, Katherine P, et al.
Publicado: (2022)

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma
por: Gargett, Tessa, et al.
Publicado: (2022)

Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice
por: Dong, Xinyue, et al.
Publicado: (2023)

Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers
por: Ba, Hongping, et al.
Publicado: (2023)

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy
por: Lee, Lydia, et al.
Publicado: (2023)

Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy
por: Johnson, P Connor, et al.
Publicado: (2022)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness
por: Bachiller, Mireia, et al.
Publicado: (2021)

Automated, scaled, transposon-based production of CAR T cells
por: Lock, Dominik, et al.
Publicado: (2022)

CD47 expression is critical for CAR T-cell survival in vivo
por: Beckett, Alex N, et al.
Publicado: (2023)

Large-scale manufacturing and characterization of CMV-CD19CAR T cells
por: Wang, Xiuli, et al.
Publicado: (2022)

Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors
por: Mandriani, Barbara, et al.
Publicado: (2022)

Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells
por: Martín-Otal, Celia, et al.
Publicado: (2022)

Serpin B9 controls tumor cell killing by CAR T cells
por: Kimman, Thomas, et al.
Publicado: (2023)

Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19(+) malignancy
por: Pennell, Christopher A, et al.
Publicado: (2022)

Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor
por: Zhang, Boning, et al.
Publicado: (2020)

First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
por: Anna, François, et al.
Publicado: (2021)

Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Huckaby, Justin T, et al.
Publicado: (2021)

CARs and beyond: tailoring macrophage-based cell therapeutics to combat solid malignancies
por: Abdin, Shifaa M., et al.
Publicado: (2021)

Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
por: Sun, Ming, et al.
Publicado: (2023)

CAR T-cell detection scoping review: an essential biomarker in critical need of standardization
por: Turicek, David P, et al.
Publicado: (2023)

Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia
por: Wen, Jingjing, et al.
Publicado: (2023)

Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts
por: Quintarelli, Concetta, et al.
Publicado: (2021)

CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity
por: Jess, Jennifer, et al.
Publicado: (2023)

Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells
por: Fang, Karen Kai-Lin, et al.
Publicado: (2023)

Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma
por: McKenna, Mary K, et al.
Publicado: (2023)

Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma
por: Sun, Luan, et al.
Publicado: (2021)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Deletion of Cbl-b inhibits CD8(+) T-cell exhaustion and promotes CAR T-cell function
por: Kumar, Jitendra, et al.
Publicado: (2021)

Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
por: Schoutrop, Esther, et al.
Publicado: (2023)

Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model
por: Ranoa, Diana Rose E, et al.
Publicado: (2023)

Fully human antibody V(H) domains to generate mono and bispecific CAR to target solid tumors
por: Wang, Guanmeng, et al.
Publicado: (2021)

VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding
por: Lanitis, Evripidis, et al.
Publicado: (2021)

Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells
por: Kuo, Yi-Chiu, et al.
Publicado: (2022)

Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
por: Camviel, Nicolas, et al.
Publicado: (2022)

Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse
por: Liu, Lunan, et al.
Publicado: (2022)

Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
por: Michels, Kathryn R, et al.
Publicado: (2023)

Framework humanization optimizes potency of anti-CD72 nanobody CAR-T cells for B-cell malignancies
por: Temple, William C, et al.
Publicado: (2023)

Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy
por: Zhang, Zhen, et al.
Publicado: (2020)

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
por: Han, Lu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gl7kqilfd437n5jil5gneadd0d